ArticleCureus2025
Systemic Immune-Inflammation Index as a Predictor of Progression in Melanoma: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating Cytokines in Melanoma Prognosis: Current Evidence and Future Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation plays a pivotal role in melanoma progression through mechanisms of immune suppression, angiogenesis, and metastatic dissemination. The systemic immune-inflammation index (SII), integrating platelet, neutrophil, and lymphocyte counts, has emerged as a composite biomarker reflecting the balance between tumor-promoting inflammation and host immune response.
objectiveThis study aimed to evaluate the prognostic value of the SII in predicting 12-month progression-free survival (PFS) in patients with melanoma and to determine whether elevated SII independently correlates with disease progression after adjustment for clinical stage and age.
methodsA retrospective cohort study was conducted, including 40 patients with histopathologically confirmed melanoma between 2019 and 2024. Baseline SII was calculated as (platelet count × neutrophil count) / lymphocyte count, using a validated cutoff of 560. Statistical analyses were performed using
resultsAn SII ≥560 was significantly associated with higher progression risk (relative risk (RR) 5.3; odds ratio (OR) 22.7, 95% confidence interval (CI) 4.4-117.5; p < 0.001). Patients with elevated SII had markedly reduced 12-month PFS (20% vs. 85%; log-rank = 16.5, p < 0.001). SII showed excellent discriminative ability (area under the curve (AUC) 0.91, 95% CI 0.83-0.99). In multivariable analysis, SII remained independently predictive of progression (adjusted OR 14.6; 95% CI 2.3-91.8; p = 0.004).
conclusionThe SII independently predicted 12-month disease progression in melanoma, identifying high-risk patients even within early stages. These findings support its role as a simple, reproducible, and low-cost biomarker for preoperative risk assessment and individualized follow-up. Future prospective multicenter studies with larger cohorts and extended follow-up are warranted to validate these results and to better define the clinical utility of SII as part of comprehensive melanoma risk stratification strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.